Atea Pharmaceuticals to Present at the 8th Annual Evercore Healthcare Conference

BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Wednesday, December 3, 2025 at 10:00 a.m. ET in Coral Gables, FL.

GlobeNewsWire • Nov 19, 2025

Atea Pharmaceuticals, Inc. (AVIR) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements Transcript

Atea Pharmaceuticals, Inc. ( AVIR ) Discusses Next-Generation Hepatitis C Treatment Developments and Clinical Advancements November 13, 2025 10:00 AM EST Company Participants Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Conference Call Participants Jordan Feld Anthony Martinez Nancy Reau Eric Lawitz Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Good morning, and welcome to the Atea Pharmaceuticals Virtual KOL event.

Seeking Alpha • Nov 13, 2025

Atea Pharmaceuticals, Inc. (AVIR) Q3 2025 Earnings Call Transcript

Atea Pharmaceuticals, Inc. ( AVIR ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Jonae Barnes - Senior Vice President of Investor Relations & Corporate Communications Jean-Pierre Sommadossi - Founder, Chairman, CEO & President Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - CFO, Executive VP of Legal & Secretary Conference Call Participants Selina Zhou Tsan-Yu Hsieh - William Blair & Company L.L.C., Research Division Presentation Operator Good afternoon, everyone, and welcome to the Atea Pharmaceuticals Third Quarter 2025 Financial Results and Business Update Conference Call.

Seeking Alpha • Nov 13, 2025

Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026  New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting ® , the Annual Meeting of AASLD, Support Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Therapy for the Treatment of HCV Company Announces New Hepatitis E Virus (HEV) Development Program Company Holding Conference Call Today at 4:30 PM ET Company Hosting HCV KOL Event November 13 th at 10 AM ET BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today reported financial results for the third quarter ended September 30, 2025, announced new research findings, including evidence of a unique dual mechanism of action for bemnifosbuvir against hepatitis C virus (HCV) and the expansion of the Company's antiviral pipeline with a new hepatitis E virus (HEV) program, and provided a business update. The Company's combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of HCV is currently being evaluated in a global Phase 3 development program.

GlobeNewsWire • Nov 12, 2025

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ET

GlobeNewsWire • Nov 7, 2025

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 12, 2025, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2025, and to provide a business update.

GlobeNewsWire • Nov 5, 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025

BOSTON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a virtual key opinion leader (KOL) event on Thursday, November 13, 2025 at 10:00 AM ET to discuss a wide range of hepatitis C virus (HCV)-related topics including the current HCV patient population, the importance of early diagnosis and treatment, public policy initiatives including the test-and-treat model of care, whether HCV eradication in North America is an achievable goal, and what a new optimized HCV therapy could provide for prescribers and patients. To register, click here.

GlobeNewsWire • Oct 22, 2025

Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that new data will be presented supporting the combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor and ruzasvir, an NS5A inhibitor, as a potential best-in-class regimen for the treatment of hepatitis C (HCV) infection at The Liver Meeting® 2025, the annual meeting of the American Association for the Study of Liver Diseases (AASLD). Accepted for presentations were three abstracts detailing multi-scale HCV modeling results and a viral resistance analysis both from the Phase 2 study evaluating the combination regimen of bemnifosbuvir and ruzasvir and results from a Phase 1 study investigating whether there is a food effect with the fixed-dose combination of bemnifosbuvir and ruzasvir.

GlobeNewsWire • Oct 7, 2025

Atea Pharmaceuticals, Inc. (AVIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:05 PM EDT Company Participants Janet Hammond - Chief Development Officer Maria Horga - Chief Medical Officer John Vavricka - Chief Commercial Officer Andrea Corcoran - CFO, Executive VP of Legal & Secretary Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity Analyst Great. Hello, everyone.

Seeking Alpha • Sep 9, 2025

Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that members of the Atea management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 1:05 p.m.

GlobeNewsWire • Sep 2, 2025